Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400919 | 1.00 | GPR119 (0.38) | GPR119MAPTHCRTR2CYP2C9CYP2C19 | |
| SCHEMBL12356487 | 0.91 | GPR119 (0.39) | GPR119MAPTHCRTR2CYP2C9CYP2C19 | |
| SCHEMBL2246273 | 0.91 | GPR119 (0.39) | GPR119MAPTHCRTR2CYP2C9CYP2C19 | |
| SCHEMBL12367370 | 0.91 | GPR119 (0.39) | GPR119MAPTHCRTR2CYP2C9CYP2C19 | |
| SCHEMBL3403746 | 0.89 | MAPT (0.35) | GPR119MAPTHSP90AB1 | |
| SCHEMBL12356460 | 0.88 | GPR119 (0.42) | GPR119MAPTHCRTR2CYP2C9CYP2C19 | |
| SCHEMBL2243540 | 0.83 | MAPT (0.40) | GPR119MAPTHCRTR2CYP2C9CYP2C19 | |
| SCHEMBL2247536 | 0.78 | MAPT (0.31) | MAPT | |
| SCHEMBL2246278 | 0.77 | MAPT (0.31) | MAPTHSP90AB1 | |
| SCHEMBL2249655 | 0.73 | GPR119 (0.41) | GPR119MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | claimed |
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885MAPT 4009/4885HCRTR2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.